Is the Sars-CoV-2 virus a possible trigger agent for the development of achalasia?
Authors:
- Janette Furuzawa-CarballedaJFJanette Furuzawa-Carballeda
- Diana Aguilar-LeónDADiana Aguilar-León
- Norma Uribe-UribeNUNorma Uribe-Uribe
- Dheni A. Fernández-CamargoDFDheni A. Fernández-Camargo
- Coss-Adame E EnriqueCECoss-Adame E Enrique
- Miguel A. ValdovinosMVMiguel A. Valdovinos
- Luis A. Chi-CerveraLCLuis A. Chi-Cervera
Preprint
Abstract
BACKGROUND: Previous studies have suggested that achalasia is an autoimmune disease whose probable causal agent is a neurotropic virus that chronically infects the myenteric plexus of the esophagus and, in a genetically susceptible host, induces the disease. The association between achalasia and coronaviruses has not been reported in the literature. AIMS: To evaluate the presence of the SARS-CoV-2 virus, the ACE2 expression, the tissue architecture, and immune response in the lower esophageal sphincter muscle (LESm) of achalasia patients who had SARS-CoV-2 (achalasia-COVID-19) infection before laparoscopic Heller myotomy (LHM) and compare the findings with type II achalasia patients and transplant donors (controls) without COVID-19. METHODS: The LESm of 7 achalasia-COVID-19 patients (diagnosed by PCR), ten achalasia patients, and ten controls without COVID-19 were included. The presence of the virus was evaluated by in situ PCR and immunohistochemistry. ACE2 receptor expression and effector CD4 T cell and regulatory subsets were determined by immunohistochemistry. RESULTS: Coronavirus was detected in 6/7 patients-COVID-19. The SARS-CoV-2 was undetectable in the LESm of the achalasia patients and controls. The ACE2 receptor was expressed in all the patients and controls. One patient developed achalasia type II post-COVID-19. The percentage of Th22/Th17/Th1/pDCreg was higher in achalasia and achalasia-COVID-19 pre-HLM vs. controls. The Th2/Treg/Breg cell percentages were higher only in achalasia vs. controls. CONCLUSION: The presence of the SARS-CoV2 and its receptor in the LESm of type II achalasia-COVID-19 patients but not in the controls suggests that it could affect the myenteric plexus. Unlike achalasia, patients-COVID-19 have an imbalance between effector CD4 T cells and the regulatory mechanisms.Keywords
All Related Versions
- Published version: Neurogastroenterology & Motility, 35 (3), e14502.
This publication has 22 references indexed in Scilit:
- An original Eurasian haplotype, HLA-DRB1*14:54-DQB1*05:03, influences the susceptibility to idiopathic achalasiaPLOS ONE, 2018
- Viral Spread to Enteric Neurons Links Genital HSV-1 Infection to Toxic Megacolon and LethalityCell Host & Microbe, 2016
- The Pathogenesis and Management of Achalasia: Current Status and Future DirectionsGut and Liver, 2015
- AchalasiaJAMA, 2015
- The Chicago Classification of esophageal motility disorders, v3.0Neurogastroenterology & Motility, 2014
- AchalasiaThe Lancet, 2014
- Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography1Neurogastroenterology & Motility, 2012
- T Cells in the Myenteric Plexus of Achalasia Patients Show a Skewed TCR Repertoire and React to HSV-1 AntigensAmerican Journal of Gastroenterology, 2008
- Achalasia: a disease of varied and subtle symptoms that do not correlate with radiographic findingsAmerican Journal of Gastroenterology, 2002
- The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in miceArchives of Virology, 2002